Table 1.

Important phase III trials of apalutamide.

Acronym	Identifier	Patient population	Comparator arms	Primary endpoint
ACIS	NCT02257736	mCRPC	Apalutamide/abiraterone/prednisone versus placebo/abiraterone/prednisone	Radiographic progression-free survival
TITAN	NCT02489318	mHSPC	Apalutamide/ADT versus placebo/ADT	Radiographic progression-free survival and overall survival
ATLAS	NCT02531516	High-risk or locally advanced prostate cancer	Apalutamide/ADT + RT versus bicalutamide/ADT + RT	Metastasis-free survival
EORTC	NCT03488810	Intermediate and limited high-risk prostate cancer	Apalutamide/ADT + RT versus nonsteroidal anti-androgen / ADT + RT	Disease-free survival
ALLIANCE	NCT03009981	Biochemically recurrent prostate cancer with PSA doubling time ⩽9 months	Degarelix versus degarelix/apalutamide versus degarelix/apalutamide/abiraterone/prednisone	PSA progression-free survival
SPARTAN	NCT01946204	nmCRPC	Apalutamide/ADT versus placebo/ADT	Metastasis-free survival

ADT, androgen deprivation therapy; mCRPC, metastatic castrate-resistant prostate cancer; mHSPC, metastatic hormone-sensitive prostate cancer; nmCRPC, nonmetastatic castrate-resistant prostate cancer; PSA, prostate-specific antigen; RT, radiotherapy.